| Literature DB >> 34831608 |
Fabiana Angélica de Paula1, Vanessa Amaral Mendonça2, Vanessa Kelly da Silva Lage1, Guilherme Pinto da Silva3, Hellen Cristina de Almeida1, Liliana Pereira Lima1, Joyce Noelly Vítor Santos3, Daniela Pereira de Castro4, Camila Franciele da Paixão4, Ana Luiza da Silva Nunes Teixeira Rodrigues4, Vinícius Cunha de Oliveira3, Pedro Henrique Scheidt Figueiredo3, Mario Bernardo-Filho5, Ana Cristina Rodrigues Lacerda6, Redha Taiar7.
Abstract
Whole-body vibration (WBV) exercises have recently been introduced as a nonpharmacological therapeutic strategy for sarcopenic older people. The present study aimed to evaluate the effect of WBV exercise on hemodynamic parameters in sarcopenic older people. Forty older people, divided into groups of nonsarcopenic (NSG = 20) and sarcopenic (SG = 20), participated in the study and were cross randomized into two interventions of eight sets of 40 s each, these being squatting with WBV and squatting without WBV. Heart rate (HR), peak heart rate (peak HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), double product (DP), mean arterial pressure (MAP), and subjective perception of effort (SPE), were assessed at baseline, during, and after a single WBV session. The HR, peak HR, and DP variables were similar at baseline between groups. WBV exercise increased all the hemodynamic parameters both during and immediately after the intervention, in both groups (SG and NSG). The MAP values were similar at baseline between groups; however, in the NSG there was a significant increase during and immediately after the squatting with WBV intervention (p < 0.05). The HR behavior, in both groups, showed that there was an increase in HR after the first set of exercises with vibration and this increase was maintained until the final set. The absence of adverse effects of WBV exercise on the cardiovascular system and fatigue suggests this exercise modality is adequate and safe for sarcopenic older people.Entities:
Keywords: hemodynamic responses; older people; physical exercise; sarcopenia; whole-body vibration
Mesh:
Year: 2021 PMID: 34831608 PMCID: PMC8617886 DOI: 10.3390/ijerph182211852
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart of the participants.
Clinical, demographic and functional characteristics of participants at baseline.
| Characteristics | NSG | SG | |
|---|---|---|---|
| Demographic and body composition | |||
| Age (years) | 72.4 (69.1–75.8) | 71.6 (67.7–75.5) | 0.73 |
| Sex (Men/Women) | 11/9 | 11/9 | |
| BMI (kg/m2) | 24.9 (23.7–26.2) | 21.2 (20.2–22.2) |
|
| BF (%) | 32.8 (29.8–35.8) | 31.7 (27.8–35.7) | 0.65 |
| Lean mass (kg) | 39.4.1 (35.9–42.8) | 33.4 (30.1 -36.6) |
|
| Fat mass (kg) | 19.1 (17.2–20.9) | 15.5 (13.4–17.7) |
|
| RSMI Men | 8.0 (7.5–8.6) | 6.5 (6.1–6.9) |
|
| RSMI Women | 6.4 (5.9–6.7) | 5.2 (5.0–5.4) |
|
| Strength and functional tests | |||
| 10.7 (10.3–11.2) | 10.1 (9.5–10.8) | 0.21 | |
| 5STS (s) | 9.1 (8.3–9.8) | 10.9 (9.8–12.1) |
|
| Walking speed (m/s) | 1.9 (1.7–2.0) | 1.7 (1.5–1.8) | 0.06 |
| Handgrip strength (kgf) | 34.8 (30.7–39.0) | 31.8 (27.0–36.5) | 0.31 |
| Men Handgrip strength (kgf) | 41.2 (34.5–47.9) | 41.2 (38.9–43.4) | 0.98 |
| Women Handgrip strength (kgf) | 29.6 (26.4–32.8) | 24.1 (19.6–28.6) | 0.05 |
| Medicines | |||
| Antihypertensives | 9 (45%) | 9 (45%) | |
| Statins | 1 (5%) | 3 (15%) | |
| Oral antidiabetics | 0 (0%) | 1 (5%) | |
| Anticoagulant | 1 (5%) | 0 (0%) | |
| Antirheumatics | 0 (0%) | 1 (5%) | |
| Antidepressants | 1 (5%) | 0 (0%) | |
| None | 10 (50%) | 11 (55%) |
Values are means (95% CI), number, and percentage. NSG: Nonsarcopenic group. SG: Sarcopenic group. BMI: Body Mass Index, BF: Body Fat, RSMI: Relative Skeletal Muscle Mass Index, SPPB: Short Physical Performance Battery, STS: Sit-to-Stand test. Bold values denote statistical significance at the p < 0.05 level.
Figure 2Immediate hemodynamic responses in the interventions with and without whole-body vibration in nonsarcopenic and sarcopenic groups. Data are means and standard deviation. Two-way ANOVA for repeated measures and post hoc Bonferroni. Significance * difference between “rest”; # difference between “during”, and & difference between WBV vs. without WBV (p < 0.05). Difference between the mean values at rest between groups (a # b). (A)—HR: heart rate; (B)—peak HR; (C)—Systolic Blood Pressure (SBP); (D)—Diastolic Blood Pressure (DBP); (E)—MAP: mean arterial pressure; (F)—DP: double product; (G)—SPE: subjective perception of effort.
Figure 3Heart rate (HR) behavior after each set of exercises in situations with and without whole-body vibration in the nonsarcopenic (A) and sarcopenic (B) groups.
Comparison of hemodynamic parameters between the interventions in the nonsarcopenic and the sarcopenic group.
| Outcomes | Intervention | NSG | SG |
|---|---|---|---|
| Δ HR, bpm | Without WBV | 1.80 (−0.82–4.43) | 3.50 (0.90–6.2) |
| WBV | 6.30 (3.68–8.92) | 7.10 (4.44–9.70) | |
| Mean Difference | 4.50 (0.78–8.20) * | 3.50 (−0.177–7.24) | |
| Δ peak HR, bpm | Without WBV | 4.90 (2.20–7.60) | 7.20 (4.46–9.94) |
| WBV | 11.60 (8.86–14.34) | 13.55 (10.81–16.30) | |
| Mean Difference | 6.70 (2.83–10.57) * | 6.35 (2.47–10.22) * | |
| Δ SBP, mmHg | Without WBV | −2.00 (−6.54–2.54) | −1.00 (−5.54–3.54) |
| WBV | 4.00 (−0.54–8.54) | −2.00 (−6.54–2.54) | |
| Mean Difference | 6.00 (−0.42–12.42) | 1.00 (−5.42–7.42) | |
| Δ DBP, mmHg | Without WBV | 0.00 (−3.50–3.50) | −0.50 (−3.40–2.99) |
| WBV | 1.50 (−1.99–4.99) | 2.00 (−1.50–5.50) | |
| Mean Difference | 1.50 (−3.44–6.44) | 2.50 (−2.44–7.44) | |
| Δ MAP, mmHg | Without WBV | 0.17 (−4.80–5.13) | 1.17 (−3.80–6.13) |
| WBV | −10.67 (−15.63–−5.70) | 2.66 (−2.30–7.63) | |
| Mean Difference | −10.83 (−17.85–−3.81) * | −1.50 (−8.52–−5.52) | |
| Δ DP, mmHg, bpm | Without WBV | 110.60 (−370.36 −591.56) | 365.90 (−115.06–846.86) |
| WBV | 1160.75 (679.73–1641.70) | 822.85 (341.90–1303.80) | |
| Mean Difference | 1050.15 (369.97–1730.33) * | 456.95 (−223.23–1137.13) | |
| Without WBV | 0.00 (−0.05–0.05) | 0.00 (−0.056–0.056) | |
| Δ SPE, points | WBV | 0.05 (−0.006–0.106) | 0.02 (−0.03–0.08) |
| Mean Difference | −0.05 (-0.13–0.03) | −0.02 (−0.10–0.05) |
Values are means (95% CI). HR: heart rate; peak HR: peak heart rate; systolic blood pressure (SBP); diastolic blood pressure (DBP); MAP: mean arterial pressure; DP: double product; SPE: subjective perception of effort. NSG: Nonsarcopenic group and SG: Sarcopenic group. Experimental design in randomized blocks (between-intervention, within-intervention, interaction analyses). Two-way ANOVA (2 intervention vs. 2 moments), in both groups (nonsarcopenic and sarcopenic). * Post hoc Bonferroni significance.
Effects and interaction values found by Two-way ANOVA analysis of the data presented in Table 2.
| Outcomes | Between Groups | Within Groups | Interaction | |||
|---|---|---|---|---|---|---|
|
| F |
| F |
| F | |
| Δ HR, bpm | 0.35 | 0.89 |
| 9.3 | 0.72 | 0.13 |
| Δ peak HR, bpm | 0.12 | 2.38 |
| 22.51 | 0.89 | 0.02 |
| Δ SBP, mmHg | 0.28 | 1.20 | 0.28 | 1.20 | 0.13 | 2.36 |
| Δ DBP, mmHg | 1.00 | 0.00 | 0.26 | 1.30 | 0.78 | 0.08 |
| Δ MAP, mmHg |
| 8.27 | 0.06 | 3.50 |
| 6.12 |
| Δ DP, mmHg, bpm | 0.86 | 0.03 |
| 9.74 | 0.22 | 1.50 |
| Δ SPE, points | 0.65 | 0.20 | 0.18 | 1.80 | 0.65 | 0.20 |
Legend: HR: heart rate; peak HR: peak heart rate; systolic blood pressure (SBP); diastolic blood pressure (DBP); MAP: mean arterial pressure; DP: double product; SPE: subjective perception of effort. NSG: Nonsarcopenic group and SG: Sarcopenic group. Experimental design in randomized blocks (between-intervention, within-intervention, interaction analyses). Two-way ANOVA (2 intervention vs. 2 moments), in both groups (nonsarcopenic and sarcopenic). Bold values denote statistical significance at the p < 0.05 level.